Date: 21 Oct 2012
Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Candida albicans is the most frequently isolated yeast from the oral cavity of HIV/AIDS individuals. The use of fluconazole has increased the number of resistant or less-sensitive Candida species different than C. albicans. The purpose of this study was to identify the Candida species producing pseudomembranous candidiasis in patients suffering from AIDS, their relationship with CD4+ counts and their sensitivity to fluconazole and itraconazole. We studied 71 patients at a hospital in the city of Cali. Samples of white plaque were seeded on CHROMagar Candida, yeast identification was done with API 20C Aux, and susceptibility testing was determined by E test. Ninety-three yeast isolates were obtained, 52 single and 41 mixed. C. albicans was the most isolated, followed by C. glabrata. An increased frequency of isolates and variety of Candida species occurred in patients with a CD4+ cell count ≤100 cells/mm3 without significant differences (p = 0.29). The susceptibility study showed that 8 (8.6 %) isolates were resistant to fluconazole and 11 (11.8 %) to itraconazole, while 6 (8.8 %) C. albicans were simultaneously resistant. No association was found between the isolates of C. albicans or Candida species different than C. albicans and the use of fluconazole (p = 0.21). The results of this study indicate that in the tested population, fluconazole continues to be the best treatment option for oropharyngeal candidiasis in patients suffering from AIDS (HIV/AIDS); however, susceptibility tests are necessary in patients who present therapeutic failure.
Pinzón EM, Bravo SM, Méndez F, Clavijo GM, León ME. Prevalencia y factores relacionados con la presencia de manifestaciones orales en pacientes con VIH/SIDA, Cali, Colombia. Colomb Med. 2008;39:346–55.
Aguirre-Urízar JM, Echebarría-Goicouría MA, Eguía-del-Valle A. Acquired immunodeficiency syndrome: manifestations in the oral cavity. Med Oral Patol Oral Cir Bucal. 2004;9(Suppl):153–7.PubMed
Sant’Ana P, Milan EP, Martinez R, Queiroz-Telles F, Ferreira MS, Alcântara AP, et al. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz. 2002;97:253–7.CrossRef
Nadagir SD, Chunchanur SK, Halesh LH, Yasmeen K, Chandrasekhar MR, Patil BS. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients. Southeast Asian J TropMed Public Health. 2008;39:492–5.
Masiá Canuto M, Gutiérrez Rodero F, Ortiz de la Tabla Ducasse V, Hernández Aguado I, Martín González C, Sánchez Sevillano A, et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000;19:593–601.
Gutiérrez C, de Bedout C, Tobón AM, Cano LE, Arango M, Tabares AM, et al. Sensibilidad a fluconazol y voriconazol de aislamiento de Candida spp., obtenidos de aislamientos de mucosa oral de pacientes con sida. Infectio. 2007;11:183–9.
Mendoza N, Arora A, Motta A, Arias C. Prevalence of oral candidiasis in the HAART era in developing countries: A cohort from Colombia. J Am Acad Dermatol. 2008; 58 S2 AB94.
Gales AC, Pfaller MA, Houston AK, Joly S, Sullivan DJ, Coleman DC, et al. Identification of Candida dubliniensis based on temperature and utilization of xylose and α-methyl-D-glucoside as determined with the API 20C AUX and Vitek YBC systems. J Clin Microbiol. 1999;37:3804–8.PubMed
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd Informational Supplement, M27–S3. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A. CLSI subcommittee for antifungal susceptibility testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180–95.PubMedCrossRef
Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012;50:2040–6.PubMedCrossRef
Mane A, Panchvalli S, Bembalkar S, Risbud A. Species distribution & antifungal susceptibility of oral Candida colonising or infecting HIV infected individuals. Indian J Med Res. 2010;131:836–8.PubMed
Maninder J, Usha A. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients. J Commun Dis. 2008;40:177–81.PubMed
Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme. Mycopathologia. 2012 May 13. [Epub ahead of print].
Delgado W, Aguirre JM. Las micosis orales en la era del sida. Rev Iberoam Micol. 1997;14:14–22.PubMed
Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2004;97:47–52.CrossRef
Barchiesi F, Colombo AL, McGough DA, Forhergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and—resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994;38:1530–3.PubMedCrossRef
- Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia
Volume 175, Issue 1-2 , pp 91-98
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Oropharyngeal candidiasis
- Candida albicans
- Candida species different than C. albicans
- CD4+ Lymphocytes
- Industry Sectors
- Author Affiliations
- 1. School of Bacteriology and Clinical Laboratory, Universidad del Valle, Cali, Colombia
- 2. Department of Microbiology, Universidad del Valle, Cali, Colombia
- 3. Department of Internal Medicine, Universidad del Valle, University Hospital of Valle, Cali, Colombia